167 related articles for article (PubMed ID: 35151192)
1. Lacosamide effectiveness and tolerability in patients with drug-resistant epilepsy and severe disability under polytherapy: Therapy optimization as emerging from an observational study.
Pozzi M; Zanotta N; Epifanio R; Baldelli S; Cattaneo D; Clementi E; Zucca C
Epilepsy Behav; 2022 Mar; 128():108598. PubMed ID: 35151192
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide.
Talha Özgün O; Kandemir Yılmaz M; Mert Atmaca M; Keskin Güler S; Buluş E; Duman A; Çelebi Ö; Gürses C
Epilepsy Behav; 2023 Aug; 145():109355. PubMed ID: 37473655
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience combined with therapeutic drug monitoring of lacosamide.
Svendsen T; Brodtkorb E; Baftiu A; Lossius MI; Nakken KO; Johannessen SI; Johannessen Landmark C
Acta Neurol Scand; 2020 Apr; 141(4):279-286. PubMed ID: 31853958
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the efficacy and influencing factors of sodium channel blockers in the treatment of focal epilepsy in infants under 6 months of age].
Ma YP; Deng J; Fu ZR; Chen CH; Wang XH; Wang X; Weng JW; Shen YH
Zhonghua Er Ke Za Zhi; 2023 Nov; 61(11):983-988. PubMed ID: 37899337
[No Abstract] [Full Text] [Related]
5. Lacosamide in patients with intellectual disability and refractory epilepsy.
Kleist A; Kerling F; Hamer H; Winterholler M
Acta Neurol Belg; 2019 Sep; 119(3):423-430. PubMed ID: 30840220
[TBL] [Abstract][Full Text] [Related]
6. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs.
Sake JK; Hebert D; Isojärvi J; Doty P; De Backer M; Davies K; Eggert-Formella A; Zackheim J
CNS Drugs; 2010 Dec; 24(12):1055-68. PubMed ID: 21090839
[TBL] [Abstract][Full Text] [Related]
7. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain.
Casas-Fernández C; Martínez-Bermejo A; Rufo-Campos M; Smeyers-Durá P; Herranz-Fernández JL; Ibáñez-Micó S; Campistol-Plana J; Alarcón-Martínez H; Campos-Castelló J
Drugs R D; 2012 Dec; 12(4):187-97. PubMed ID: 23193979
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of add-on therapy with newer-generation antiepileptic drugs in Bulgarian patients with refractory epilepsy.
Viteva E; Zahariev Z
Epilepsy Behav; 2018 Oct; 87():137-145. PubMed ID: 30097339
[TBL] [Abstract][Full Text] [Related]
10. Lacosamide add-on therapy for partial epilepsy.
Weston J; Shukralla A; McKay AJ; Marson AG
Cochrane Database Syst Rev; 2015 Jun; (6):CD008841. PubMed ID: 26077821
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study.
Rosati A; Ilvento L; Rizzi R; Doccini V; Leo MC; Pugi A; De Masi S; Guerrini R
Epilepsia; 2018 May; 59(5):1004-1010. PubMed ID: 29663335
[TBL] [Abstract][Full Text] [Related]
12. Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.
Becerra JL; Ojeda J; Corredera E; Ruiz Giménez J
CNS Drugs; 2011 Dec; 25 Suppl 1():3-16. PubMed ID: 22141347
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES).
Rudà R; Houillier C; Maschio M; Reijneveld JC; Hellot S; De Backer M; Chan J; Joeres L; Leunikava I; Glas M; Grant R
Epilepsia; 2020 Apr; 61(4):647-656. PubMed ID: 32329527
[TBL] [Abstract][Full Text] [Related]
14. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study.
Rocamora R; Ley M; Molins A; Toledo M; Sansa G; Bertol V; Becerra JL; Carreño M; Mauri JÁ
Epilepsy Behav; 2018 Feb; 79():87-92. PubMed ID: 29253680
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study.
Toupin JF; Lortie A; Major P; Diadori P; Vanasse M; Rossignol E; D'Anjou G; Perreault S; Larbrisseau A; Carmant L; Birca A
Epileptic Disord; 2015 Dec; 17(4):436-43. PubMed ID: 26609635
[TBL] [Abstract][Full Text] [Related]
16. Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: a real-world study.
Zhao T; Yu LH; Zhang HL; Yu J; Feng J; Wang TT; Sun Y; Li HJ
BMC Pediatr; 2023 May; 23(1):249. PubMed ID: 37210552
[TBL] [Abstract][Full Text] [Related]
17. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy.
Grosso S; Parisi P; Spalice A; Verrotti A; Balestri P
Eur J Paediatr Neurol; 2014 Jan; 18(1):55-9. PubMed ID: 24129195
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range.
Yamamoto Y; Terada K; Araki Y; Fukushima Y; Imai K; Kagawa Y; Takahashi Y
Ther Drug Monit; 2020 Oct; 42(5):754-759. PubMed ID: 32941398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
